William Blair Has Pessimistic Outlook of Envista Q1 Earnings

Envista Holdings Co. (NYSE:NVST) – Investment analysts at William Blair reduced their Q1 2025 earnings per share (EPS) estimates for shares of Envista in a report released on Thursday, February 6th. William Blair analyst B. Vazquez now forecasts that the company will earn $0.21 per share for the quarter, down from their previous forecast of $0.27. The consensus estimate for Envista’s current full-year earnings is $1.06 per share. William Blair also issued estimates for Envista’s Q2 2025 earnings at $0.22 EPS, Q3 2025 earnings at $0.21 EPS, FY2025 earnings at $0.97 EPS and FY2026 earnings at $1.06 EPS.

NVST has been the subject of several other reports. Needham & Company LLC reaffirmed a “hold” rating on shares of Envista in a research note on Thursday, February 6th. Morgan Stanley boosted their target price on Envista from $19.00 to $20.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 6th. Robert W. Baird boosted their target price on Envista from $17.00 to $22.00 and gave the stock a “neutral” rating in a research report on Thursday, October 31st. Jefferies Financial Group boosted their target price on Envista from $20.00 to $22.00 and gave the stock a “hold” rating in a research report on Thursday, January 23rd. Finally, Leerink Partners upgraded Envista from an “underperform” rating to a “market perform” rating and boosted their target price for the stock from $16.00 to $23.00 in a research report on Thursday, October 31st. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, Envista presently has an average rating of “Hold” and a consensus target price of $20.21.

Envista Stock Down 0.0 %

NVST opened at $21.24 on Monday. The business has a 50 day moving average price of $19.94 and a two-hundred day moving average price of $19.20. The company has a quick ratio of 1.77, a current ratio of 2.04 and a debt-to-equity ratio of 0.44. The company has a market cap of $3.66 billion, a PE ratio of -3.27, a P/E/G ratio of 2.06 and a beta of 1.34. Envista has a 52 week low of $15.15 and a 52 week high of $23.06.

Envista (NYSE:NVST) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $0.24 EPS for the quarter, beating the consensus estimate of $0.23 by $0.01. Envista had a positive return on equity of 3.86% and a negative net margin of 44.56%.

Institutional Investors Weigh In On Envista

Institutional investors and hedge funds have recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Envista in the 3rd quarter worth approximately $31,000. GAMMA Investing LLC grew its holdings in Envista by 69.8% during the 3rd quarter. GAMMA Investing LLC now owns 1,766 shares of the company’s stock valued at $35,000 after buying an additional 726 shares during the last quarter. Huntington National Bank grew its holdings in Envista by 97.8% during the 3rd quarter. Huntington National Bank now owns 1,919 shares of the company’s stock valued at $38,000 after buying an additional 949 shares during the last quarter. Venturi Wealth Management LLC grew its holdings in Envista by 528.4% during the 4th quarter. Venturi Wealth Management LLC now owns 1,948 shares of the company’s stock valued at $38,000 after buying an additional 1,638 shares during the last quarter. Finally, Blue Trust Inc. grew its holdings in Envista by 69.7% during the 3rd quarter. Blue Trust Inc. now owns 1,957 shares of the company’s stock valued at $39,000 after buying an additional 804 shares during the last quarter.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.